Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423262 | 0.85 | MET (0.42) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL5337914 | 0.80 | MAP4K4 (0.41) | CYP17A1NAMPTPSMB8KDRBRAF | |
| SCHEMBL5444453 | 0.80 | KDR (0.46) | CYP17A1NAMPTP2RX3PSMB8KDR | |
| Hydrochloric Acid SCHEMBL5454555 | 0.77 | CYP17A1 (0.43) | CYP17A1NAMPTPSMB8KDRBRAF | |
| SCHEMBL14447605 | 0.77 | CYP17A1 (0.43) | CYP17A1NAMPTPSMB8KDRBRAF | |
| SCHEMBL14447606 | 0.76 | P2RX3 (0.43) | CYP17A1NAMPTP2RX3PSMB8KDR | |
| SCHEMBL14447603 | 0.75 | SIRT2 (0.42) | CYP17A1NAMPTPSMB8KDRBRAF | |
| SCHEMBL5441115 | 0.75 | KDR (0.69) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL29131710 | 0.72 | HPGD (0.59) | CYP17A1NAMPTPSMB8MAP4K4 | |
| SCHEMBL5336104 | 0.71 | CYP17A1 (0.41) | CYP17A1NAMPTKDRBRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | CYP17A1 4528/4885NAMPT 1911/4885P2RX3 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.